Pharma — India Patent Cases
730 decisions indexed
Page 14 of 25 · 730 total
Pfizer Inc & Ors. v.Natco Pharma Limited
Pfizer Inc & Ors filed a suit for permanent injunction against Natco Pharma Limited alleging infringement of patent IN 218291 covering the drug 'Palbociclib'. The parties subsequently entered into an amicable settlement agreement, which was recorded by the Court.
Bayer Healthcare Llc v.MSN Laboratories Private Limited
This order addressed various interlocutory applications in the commercial suit filed by Bayer Healthcare Llc against MSN Laboratories Private Limited. The court allowed several procedural requests, including granting time extensions and allowing additional documents. It also noted that the defendant had not yet launched its product and directed it to maintain status quo.
Otsuka Pharmaceutical Co Ltd v.The Controller Of Patents
Otsuka Pharmaceutical appealed the Controller's order refusing a patent application for a medicament combination involving Brexpiprazole, citing lack of inventive step. The appellant argued that the rejection was non-reasoned and procedurally flawed, particularly because the Respondent introduced new prior art documents (D2 and D3) without giving the Appellant an opportunity to respond. The High Court found the impugned order vitiated due to procedural infirmities and set it aside, remanding the matter for fresh consideration.
Pfizer Inc v.Azista Industries Private Limited
Pfizer Inc filed a suit seeking an injunction against Azista Industries Private Limited for infringing patent no. IN 218291, which covers the pharmaceutical product 'Palbociclib'. After considering the submissions and assurances given by the Defendants that they would not manufacture or sell the product in India, the Court decreed the suit.
M/s.Micro Labs Limited v.Mr.A.Santhosh
M/s. Micro Labs Limited filed a civil suit against Mr. A. Santhosh alleging infringement of its registered trademark 'AVAS' and copyright in its label by the use of the deceptively similar mark 'AVASLIP'. The plaintiff sought permanent injunctions, damages, and accounts of profits. However, the Madras High Court rejected the plaint, finding that the plaintiff failed to comply with the mandatory pre-institution mediation requirement stipulated under Section 12-A of the Commercial Courts Act, 2015.
Eli Lilly And Company v.Bryan Pharmaceuticals Through Its...
The suit seeks a permanent injunction against the unauthorized sale and distribution of Baricitinib, a drug used for rheumatoid arthritis, which allegedly infringes the plaintiff's patent. The case also involves claims for damages and delivery up.
Paras Ayurvedic Pharma Pvt.Ltd v.Salman Iqbal Ahmed Momin And Anr
Paras Ayurvedic Pharma Pvt.Ltd appealed against two lower court orders concerning a commercial IP suit alleging copyright infringement and passing off related to 'Roghan Sukoon Massage Oil'. The core dispute centered on whether the defendant's product copied the plaintiff's unique artistic work and brand elements, and whether the plaintiffs had sufficient knowledge of the alleged infringement. The Bombay High Court dismissed the appeal, upholding the lower court's decision that the plaintiffs were entitled to relief.
Paras Ayurvedic Pharma Pvt.Ltd v.Salman Iqbal Ahmed Momin And Anr
This commercial appeal involved a dispute over the medicinal oil 'Roghan Sukoon Massage Oil,' where Paras Ayurvedic Pharma Pvt.Ltd alleged copyright infringement and passing off against Salman Iqbal Ahmed Momin and Anr. The core issue revolved around whether the Plaintiffs had knowledge of the Defendant's allegedly infringing goods earlier than they claimed in their plaint. The Bombay High Court upheld the lower court's decision, finding no evidence to suggest that the Plaintiffs were misled or delayed in seeking relief.
Paras Ayurvedic Pharma Pvt.Ltd v.Salman Iqbal Ahmed Momin And Anr
This commercial appeal involved a dispute over the medicinal oil 'Roghan Sukoon Massage Oil,' where the Plaintiff alleged copyright infringement and passing off against the Respondent. The core issue revolved around whether the Plaintiffs had sufficient knowledge of the Defendant's impugned goods, which was central to the initial injunction granted by the lower court. The Bombay High Court upheld the previous orders, finding no infirmity in the single judges' discretion regarding the interlocutory applications.
Chugai Seiyaki Kabushiki Kaisha & Anr. v.MSN Laboratories Private Limited
The Plaintiffs filed a suit seeking permanent injunction against MSN Laboratories Private Limited for infringing Indian Patent No. 294424, which covers the tetracyclic compound 'Alectinib'. The Defendant initially claimed research use only, but subsequently provided an affidavit undertaking not to commercially launch Alectinib until the patent expires or is found invalid. The court accepted these undertakings and decreed the suit.
Ds Biopharma Limited v.The Controller Of Patents And Designs and Anr
Ds Biopharma Limited appealed the rejection of its patent application by the Assistant Controller. The Appellant argued that the grounds for rejection, particularly under Section 3(d), were not properly specified in the hearing notice, violating natural justice. The Court found that the Appellant lacked adequate opportunity to respond to the specific objection under Section 3(d).
Boehringer Ingelheim Pharma Gmbh Co v.Centurion Remedies Private Limited
The plaintiffs (Boehringer Ingelheim) filed a suit alleging that the defendants were manufacturing/importing generic versions of medicines covered by their Indian Patent No. 243301, which relates to Linagliptin compounds. The court found that the plaintiffs made out a good prima facie case and granted an ad-interim injunction restraining the defendants from manufacturing or selling the infringing products.
Janssen Pharmaceuticals & Others v.MSN Laboratories Pvt. Ltd.
Plaintiffs, exclusive licensees of a patent holder (Mitsubishi Tanabe Pharma Corporation), filed suit alleging that Defendant No. 1 was manufacturing and marketing Canagliflozin Tablets/Capsules, which falls under Indian Patent No. 232231. The defendant opposed the interim injunction, arguing that damages could be quantified and there was no irreparable loss. The court found a prima facie case in favor of the plaintiffs.
Novartis Ag v.Controller Of Patents And Designs
Novartis appealed the rejection of its divisional patent application, which was held by the Controller to be non-maintainable because it belonged to the same broad class as the granted parent application. The appeal challenged the ground that the subject matter formed a single inventive concept.
Msn Laboratories Private Limited v.Bristol Myers Squibb Holdings Ireland Unlimited Company
The petitioner filed a revocation petition under Section 64 of the Patents Act, 1970, seeking to revoke patent number 247381 covering APIXABAN. The court allowed notice and directed the completion of pleadings within prescribed timelines.
Plusplus Lifesciences Llp & Anr. v.Dr. Shiwani Singh & Ors.
The Delhi High Court granted the plaintiffs an interim injunction in a suit alleging trade secret misappropriation and trademark infringement. The court found that the defendants, former employees, had gained access to proprietary technical know-how and confidential business information regarding prenatal supplements (TRIMACARE/LAYERCARE). Based on this prima facie case, the court authorized local commissioners to seize digital data, stock of infringing products ('NUTRIEPIC' and 'UTTERCARE'), and relevant documents to prevent irreparable injury.
Novartis A G v.Supermax Drugs And Pharmaceuticals
The suit was decreed for the lifetime of Indian Patent No. 237430, prohibiting the defendants from manufacturing or selling pharmaceutical preparations containing Nilotinib.
Jansen Pharmaceuticals & Others v.Aeon Formulations Pvt. Ltd.
The plaintiffs, who are exclusive licensees of the patent holder (Mitsubishi Tanabe Pharma Corporation), filed a suit alleging that Defendant No. 1 was manufacturing and marketing Canagliflozin Tablets/Capsules, thereby infringing Indian Patent No. 232231. The court found a prima facie case in favor of the plaintiffs.
Merck Sharp And Dohme Corp v.Harman Finochem Limited
The suit was filed by Merck Sharp And Dohme Corp seeking permanent injunction against Harman Finochem Limited for infringing Patent No. 209816 related to Sitagliptin. Although an interim injunction had been granted earlier, the matter reached a settlement as the patent expired during the pendency of the suit. The Defendant agreed to pay partial litigation costs.
Pfizer Inc v.Azista Industries Private Limited
The suit was filed by Pfizer Inc seeking an injunction against the infringement of Patent No. IN 218291, which covers the pharmaceutical product 'Palbociclib'. The court condoned the delay in filing replications and made the existing ad-interim injunction absolute during the pendency of the suit.
Vifor International Ltd. v.Competition Commission Of India
Vifor International Ltd. challenged the orders of the Competition Commission of India (CCI) which initiated an inquiry into its licensing practices regarding the patent for Ferric Carboxymaltose (FCM). Vifor argued that the CCI was exceeding its jurisdiction by seeking commercially sensitive information related to a patented product, touching upon rights under the Patents Act, 1970. The High Court dismissed the writ petition, finding it premature and noting that the CCI would consider the petitioner's objections.
Novartis A G v.Supermax Drugs And Pharmaceuticals Private Limited
Novartis A G filed a suit seeking permanent injunction against Supermax Drugs And Pharmaceuticals Private Limited for infringing its patent (IN 237430) covering the drug molecule Nilotinib. The dispute arose after the Defendant submitted bids to a government tender using the patented substance. During the proceedings, the Defendants conceded that they had no intention to manufacture or sell the preparation during the patent's lifetime. Consequently, the court decreed the suit for permanent injunction, contingent upon the filing of an affidavit detailing existing stock and an undertaking to comply with the decree.
Eris Lifesciences Limited v.Controller Of Patents & Anr.
This judgment addresses applications filed by Respondent No.2 (Patentee) seeking dismissal of revocation petitions on the grounds of being time-barred. The court held that since no specific limitation is prescribed for revocation under Section 64, a three-year limitation period cannot be read into the provision. Furthermore, interim stay applications were dismissed as the patent was already granted and injunctions had been granted elsewhere.
Eris Lifesciences Limited v.Controller Of Patents & Anr.
This judgment addresses applications filed by Respondent No.2 seeking dismissal of revocation petitions concerning patent IN 243301 (Linagliptin) on the grounds that they were time-barred. The Court held that since no specific limitation period is prescribed for revocation under Section 64, a three-year limitation period cannot be read into the provision.
Glaxo Group Limited v.Glenmark Pharmaceuticals Limited
The suit was filed by Glaxo Group Limited seeking rendition of accounts and recovery of money against Glenmark Pharmaceuticals Limited concerning Patent No. IN212714. The parties subsequently reached an amicable settlement, which the Court accepted and decreed the suit in terms of that agreement.
Incyte Holding Corporation v.Assistant Controller Of Patents And Designs
Incyte Holding Corporation appealed the rejection of its patent application (No. 8686/DELNP/2010) by the Assistant Controller of Patents. The appeal was filed after a considerable delay of 530 days. The court condoned this delay, allowing the main appeal to proceed.
Merck Sharp & Dohme Corp v.Sanjeev Gupta
The commercial suit for patent infringement concerning Sitagliptin (protected by IN 209816) was settled between Merck Sharp & Dohme Corp and Sanjeev Gupta & Ors. The Defendants acknowledged the validity of the patent and agreed to cease all infringing activities, including manufacturing generic versions, until the patent expires.
Merck Sharp & Dohme LLC v.Chiral Biosciences Limited
The suit was filed seeking a permanent injunction and damages against Chiral Biosciences Limited for infringing Merck Sharp & Dohme's patent (IN 209816) covering Sitagliptin. Although the court found evidence of infringement, it ultimately denied the permanent injunction because the patent had expired by July 2022, but awarded damages and costs.
Chugai Seiyaku Kabushiki Kaisha v.Hetero Labs Limited
The Plaintiffs filed a suit seeking permanent injunction and damages against the Defendants for infringing Indian Patent No. 294424, which covers the tetracyclic compound Alectinib used in cancer treatment. The dispute centered on whether the Defendant's import and use of Alectinib Hydrochloride were commercial infringements or activities permitted under Section 107A (Bolar provision) for research and regulatory purposes.
Natco Pharma Limited v.Union Of India & Ors.
Natco Pharma Limited filed a writ petition challenging an order by the Assistant Controller that refused its application seeking cross-examination during pre-grant opposition proceedings against Novartis A.G.'s patent application (No. 4412/DELNP/2007). The court ultimately disposed of the petition, allowing for procedural steps to be taken in the underlying opposition.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.